Invion Limited (IVX.AX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Thian Chew | Executive Chairman & CEO | 422.77k | -- | -- |
| Ms. Melanie Jaye Leydin B.Bus, C.A. | CFO & Non-Executive Director | -- | -- | 1973 |
| Dr. Dean Naylor | Head of Intellectual Property Development | -- | -- | -- |
| Mr. Tai Minh Phan | Company Secretary | -- | -- | -- |
Invion Limited
- Sector:?
- Healthcare
- Industry:? Drug Manufacturers - Specialty & Generic
Description
Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, and solid cancers, such as lung, ovarian, anogenital, and glioblastoma multiforme cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Corporate Governance
Upcoming Events
August 30, 2024 at 4:55 AM UTC
Invion Limited Earnings Date
Recent Events
Recent Events Information Not Available